Fewer potential new drugs, fewer mass market opportunities, candidate drop out, declining returns...just some of today's pressures on life science companies. If only there was a way to solve the conundrum of maximising ROI as opportunities decline. Now, there is!
Under-used Asset
There is an asset all biotech companies have. It represents a large investment, and a few of them are exploiting it to the full. That asset is their investment in pharmacovigilance (PV). Integrate PV with your core activity, and you can produce developments that are easier to licence, swifter to market, quicker and more predictable in uptake, assuring your future funding.
Two key lessons emerge from all too well known industry mistakes. First, you need a 'fit for purpose' PV system to protect your portfolio asset. It must provide you with the date, from every possible AE source, that enables you to avert potential post launch disasters long before they happen. Secondly, your company must speak with one voice - a seamless, synchronous, global stance on all safety matters.
To read the article in full, please click on the pdf link below: